tbuckley/cabot-search huggingface dataset:
Bronchoscopic assessment of collateral ventilation predicts outcome of endoscopic lung volume reduction with valves
Authors: Wolfgang Gesierich, Norbert Weber, Andreas Fertl, Karl Häussinger
Journal: European Respiratory Journal (2011)

Background:  Collateral Ventilation (CV) is a cause of failure of endoscopic lung volume reduction (ELVR) with endobronchial valves (EBV). The Chartis system (PulmonX, USA) measures CV in the target lobe of ELVR to predict outcome and aid patient selection.   Aims:  To test this hypothesis we correlated Chartis values with outcome of ELVR with EBV.   Methods:  In 15 patients with severe heterogeneous emphysema we measured CV with Chartis in the target lobe of ELVR and achieved complete lobar exclusion with Zephyr EBV. We measured lung function, 6MWD, SGRQ and radiological outcome at baseline and one month.   Results:  In 2 patients a valid Chartis signal was not obtained, 3 patients showed high CV (Chartis value  10 = CV-ve). The CV-ve group compared to the CV+ve group showed significant improvement of obstruction (ΔFEV1 0,23±0,13L vs. -0,05±0,18L; p=0,018) and hyperinflation (ΔRV -1,00±0,62L vs. 0,02±0,78L; p=0,037). Δ6MWD was 58,6m vs. 43,3m (ns) and ΔSGRQ was -10,5 vs. -2,0 (ns). 10/15 patients had a response to EBV (8 CV-ve, 2 whithout valid Chartis signal). Atelectasis developed in 8/15 patients (6 CV-ve, 2 without valid Chartis signal). Of the 5/15 non-responders (ΔFEV1    Conclusions:  In our patient cohort Chartis adequately predicted outcome of ELVR with EBV in 11/15 patients. In 2 patients a valid Chartis measurement could not be obtained. 2 patients, although the Chartis reading was interpreted as CV-ve, were non-responders. Despite these limitations, Chartis in our preliminary experience seems a valuable tool to select patients for ELVR with EBV.
The Use of Cephalothin in the Treatment of Serious Infections.
Authors: Steven L. Merrill, Sydney M. Finegold, Bernard Smolens, Alvin Davis
Journal: Annals of Internal Medicine (1965)

s1 May 1965The Use of Cephalothin in the Treatment of Serious Infections.Steven L. Merrill, M.D., Sydney M. Finegold, M.D., F.A.C.P., Bernard Smolens, M.D., Alvin Davis, M.D.Steven L. Merrill, M.D.Search for more papers by this author, Sydney M. Finegold, M.D., F.A.C.P.Search for more papers by this author, Bernard Smolens, M.D.Search for more papers by this author, Alvin Davis, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-62-5-1091_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCephalothin is a new semisynthetic antibacterial agent structurally related to the penicillins. It is effective against penicillinase-producing staphylococci as well as other gram-positive and gram-negative organisms. More than 300 patients have been treated with cephalothin in this hospital over the past 2 years. Thirty-three of these patients were judged to have life-threatening infections, and the present report is concerned with these cases.Twenty-three patients with well-documented pneumonia caused byStaphylococcus aureusreceived cephalothin in doses ranging from 2 to 6 grams intramuscularly for periods from 7 to 82 days. The patients were all males, the mean age being 64. All... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California*Kindly supplied as Keflin® by Eli Lilly and Company. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1965Volume 62, Issue 5Page: 1091-1092KeywordsAntibioticsPenicillinPneumoniaStaphylococcus aureus ePublished: 1 December 2008 Issue Published: 1 May 1965 PDF downloadLoading ...
Abstract 13165: Frequency-Domain Optical Coherence Tomography Assessment of In-stent Restenosis After Percutaneous Coronary Intervention With Two-Stent Technique in Unprotected Left Main
Authors: Yusuke Fujino, Guilherme F Attizzani, Satoko Tahara, Kensuke Takagi, Toru Naganuma, Keiko Fukino, Hisaaki Ishiguro, Hiram G Bezerra, Marco A Costa, Sunao Nakamura
Journal: Circulation (2014)

Aim: FD-OCT has contributed to a better understanding of ISR; however, studies evaluating vascular response to stents and ISR pattern after two-stent technique in ULM are lacking. We aim to evaluate the ISR pattern of proximal LAD and LCX after two-stent technique in ULM.   Methods:  We performed FD-OCT in 26 patients with isolated or combined ISR (identified by angiography as >50% diameter stenosis) after DES implantation in proximal LCX and LAD after two-stent techniques. Four patients had LAD-, 13 patients had LCX- and 9 patients had both LAD and LCX-ISR. In total, 13 ISR lesions of LAD and 22 of LCX underwent FD-OCT assessments. Strut- and cross-sectional level analyses were undertaken in proximal segments of LAD and LCX (5mm distal to ostium). In addition, we compared OCT findings in the flow divider (FD) and in the lateral wall (LW) sides.   Results:  The follow-up time (days) was 386.9±426.3. In both LAD and LCX, the distance from the ostium to minimum lumen area (MLA; LAD, 2.00mm [1.00, 3.00]; LCX, 1.00mm [0.00, 1.80] distal to ostium), as well as to minimum stent area (MSA; LAD, 1.00mm [0.00, 2.00]; LCX 1.00mm [0.00, 2.00]) sites were short. Uncovered struts were more common at FD compared with LW in LAD (6.25% [0.00, 20.00] vs. 0.00% [0.00, 0.00], respectively, p=0.016) and LCX (11.32% [0.00, 19.44] vs. 0.00% [0.00, 4.55], respectively, p  Figure 1 shows the uncovered stent struts with thrombus and thicker NIH in FD of LCX.   Conclusions:  The most exacerbated NIH proliferation site in ULM bifurcation after DES implantation using two-stent techniques is located close to the ostium of LCX and LAD. While uncovered struts were more commonly found in FD of both arteries, NIH was significantly ticker in FD compared with LW in LCX and comparable between them in LAD.
Abstract P124: My Unlimited Potential: Achieving Weight, Fitness And Cardio-metabolic Health Objectives Using A 12-week, Multicomponent, Behavioral Intervention
Authors: Maribeth Rouseff, Thinh H Tran, Khurram Nasir, Josette Bou-Khalil, Joseph J Mora, Henry Guzman, Sankalp Das, Doris Brown, Joann Santiago-Charles, Teresa C Ochoa, Cynthia Gilliam, Virginia Lehn, Ehimen Aneni, Ebenezer Oni, Lara Roberson, Emir Veledar, Janisse Post, Beatriz Castillo
Journal: Circulation (2014)

Background: With about 59% of the entire US population currently in the work force, American Heart Association has emphasized worksite-based interventions to improve cardiovascular health among the working population. The primary aim of this study was to assess the short-term (12 weeks) efficacy of an ongoing multi-component, behavioral intervention improvement program (My Unlimited Potential (myUP), among employees of Baptist Health South Florida (BHSF), a large not-for-profit health care system. Methods: BHSF employees with two or more Cardio-metabolic risk factors, such as total cholesterol ≥ 200 mg/dl, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, hemoglobin A1C ≥ 6.5%, and body mass index (BMI) ≥ 30 were considered for the study. Behavioral interventions were focused on diet and physical activity modifications. Results: Overall 202 (48±10 years, 78% females) employees enrolled in myUP wellness program. The retention of subjects was high with 89% (n=181) of subjects following up at 12 weeks. The figure below demonstrates the baseline, follow-up and estimated mean change in anthropometric, exercise capacity on treadmill test and CM participants. BMI reduction &gt;5% was noted in 38% of the participants. Significantly higher, clinically meaningful, endpoints, especially in attaining blood pressure goals and exercise capacity (&gt;10 METS), during the short-term follow-up in this behavioral intervention program (figure), were achieved. Conclusion: These findings suggest that an intensive behavioral modification intervention program, delivered to employees in a health care setting, results in significant short term benefit in weight reduction, increase fitness level and concomitantly improve cardio-metabolic risk profile. Further follow-up is in progress to ascertain whether these benefits are sustainable over a longer duration.
Nonvariceal Upper Gastrointestinal Bleeding
Authors: C B Ferguson, R M Mitchell
Journal: Endoscopy (2004)

Although the incidence of nonvariceal upper gastrointestinal bleeding (NVUGIB) may be decreasing, the case fatality associated with it remains unchanged. What do the most recent studies tell us about medical and endoscopic therapy? Erythromycin is a potentially useful adjunct to endoscopy, and further data are needed to establish its role in the management of patients with NVUGIB. The use of proton-pump inhibitors in addition to combination endoscopic therapy appears to reduce the rebleeding rate consistently across different studies; the route of administration, dosage, and duration of treatment require further definition. Although two controlled studies suggest improved outcomes with clot removal and endoscopic therapy, the exact role of endoscopic treatment in the setting of overlying clots remains controversial. Hemoclips have not been found, in general, to be superior to the available endoscopic techniques. Currently, other hemostatic techniques such as injection and thermocoagulation - and in particular, combination therapy using both methods - are preferable. No major "breakthrough" endoscopic treatment has emerged. Newer endoscopic therapies such as cryotherapy are interesting, but have not had widespread application. Endoscopic suturing techniques, as used in the treatment of esophageal reflux and obesity, have not been adapted to the management of gastrointestinal bleeding.
Brassica Vegetables and Breast Cancer Risk—Reply
Authors: Stephanie A. Smith-Warner
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1887: Global gene expression analysis of tamoxifen-resistant breast cancer cell lines identified a gene signature predictive of clinical outcome of breast cancer patients treated with endocrine therapy
Authors: Daniel Elias Roro, Henriette Vever, Anne Lykkesfeldt, Henrik Ditzel
Journal: Cancer Research (2014)

Abstract Objective: Altered gene expression associated with endocrine resistance in breast cancer cell lines may have potential prognostic/predictive values in patients with ER+ breast cancer receiving endocrine therapy. In this study, we investigated mRNA expression profiles associated with the tamoxifen-resistant phenotype using a panel of isogenic MCF-7-based breast cancer cell lines to elucidate the endocrine resistance mechanism and assess whether the pattern of gene expression predicted clinical outcome in breast cancer patients treated with endocrine therapy. Method: Gene array was performed on a panel of clinically-relevant tamoxifen-resistant breast cancer cell lines (TamR) and their tamoxifen-sensitive parental cell line. Genes that showed significant alteration in expression (FDR 0.01) in TamRs vs parental cell lines were evaluated for their potential to stratify tamoxifen-treated breast cancer patients based on outcome using published gene expression data sets. Results: Using a testing set consisting of microarray data from 163 ER+ primary breast cancer patients treated with tamoxifen we identified 20 genes among those that showed significant altered expression in TamR that could stratify patients according to clinical outcome. . The potential of this 20-gene signature to stratify patients was further confirmed in 2 independent data sets consisting of ER+ tamoxifen-treated breast cancer patients with a sensitivity and specificity 53% and 79% respectively in the first cohort (N=153), and sensitivity and specificity of 37% and 91% respectively in the second cohort (N=201). Evaluation of relapse-free survival of tamoxifen-treated patients classified by the signature as having bad or good outcomes showed significant differences in time-to-relapse, with median disease-free survival times of 5.1 vs 8.9 years in the first cohort (N=153, p=0.03) and 4.2 vs 7.7 years in the second (N=201, p=0.006). Conclusions: The expression pattern of the 20-gene signature identified in this study appears to have a strong potential as a biomarker of clinical outcome of endocrine-treated breast cancer patients. Citation Format: Daniel Elias Roro, Henriette Vever, Anne Lykkesfeldt, Henrik Ditzel. Global gene expression analysis of tamoxifen-resistant breast cancer cell lines identified a gene signature predictive of clinical outcome of breast cancer patients treated with endocrine therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1887. doi:10.1158/1538-7445.AM2014-1887
Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte- macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin
Authors: SD Huan, J Hester, G Spitzer, JC Yau, FR Dunphy, RO Wallerstein, K Dicke, V Spencer, CF LeMaistre, BS Andersson
Journal: Blood (1992)
ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients
Authors: Vinay Varadan, Salendra Singh, Arman Nosrati, Lakshmeswari Ravi, James Lutterbaugh, Jill S. Barnholtz-Sloan, Sanford D. Markowitz, Joseph E. Willis, Kishore Guda
Journal: Genome Medicine (2015)

Reliable detection of somatic copy-number alterations (sCNAs) in tumors using whole-exome sequencing (WES) remains challenging owing to technical (inherent noise) and sample-associated variability in WES data. We present a novel computational framework, ENVE, which models inherent noise in any WES dataset, enabling robust detection of sCNAs across WES platforms. ENVE achieved high concordance with orthogonal sCNA assessments across two colorectal cancer (CRC) WES datasets, and consistently outperformed a best-in-class algorithm, Control-FREEC. We subsequently used ENVE to characterize global sCNA landscapes in African American CRCs, identifying genomic aberrations potentially associated with CRC pathogenesis in this population. ENVE is downloadable at https://github.com/ENVE-Tools/ENVE .
Abstract 3758: Inhibition of ATR, but not ATM, sensitizes gynecologic cancer cells to cisplatin
Authors: Pang-Ning Teng, Nicholas W. Bateman, Chad A. Hamilton, G. Larry Maxwell, Christopher J. Bakkenist, Thomas P. Conrads
Journal: Cancer Research (2014)

Abstract Resistance to platinum-based therapies remains a major hurdle in the management of gynecologic (GYN) cancer especially in ovarian cancer. Platinum such as cisplatin damages DNA by inducing DNA crosslinks that stalls DNA replication forks where significant accumulation of single-stranded DNA from persistently stalled replication forks could ultimately lead to double strand breaks and activation of apoptosis. Ataxia telangiectasia mutated (ATM) and ATM and Rad-3-related (ATR) are two main DNA damage response (DDR) protein kinases that recognize genotoxic stress and function to initiate cell cycle arrest and DNA repair mechanisms. We hypothesized by combining genotoxic stress with inhibition of DDR kinases ATR and/or ATM, therapeutic response of GYN cancer cells to platinum-based chemotherapy could be improved. To test our hypothesis, we assessed cell survival of multiple GYN cell lines including ovarian (A2780, A2780-CP20, OVCAR3), endometrial (KLE, HEC1B), and cervical (HELA, SIHA) carcinoma cells exposed to cisplatin along with ATR inhibitor (ETP-46464) and/or ATM inhibitor (KU55933). We observed inhibition of ATR significantly enhanced cisplatin induced cell death in all seven cell lines tested, resulting in 65 - 96% increased sensitivity to cisplatin. Inhibition of ATM did not sensitize GYN cancer cells to cisplatin and cells were not further sensitized by co-inhibition of ATM and ATR beyond that observed by inhibition of ATR alone. DDR signaling was assessed by immunoblotting in cells exposed to cisplatin with or without the presence of ETP-46464 and/or KU55933 where elevated levels of phospho-ATM (Ser1981), phospho-Chk2 (Thr68) and phospho-Chk1 (Ser345) observed in cisplatin treated cells were attenuated in cells that were co-treated with cisplatin and ETP-46464. In addition, increased levels of cleaved PARP1 and caspase 3 were observed in cisplatin-treated, ATR-inhibited cells, suggesting the enhancement of cisplatin induced cell death with ATR inhibition occurs through elevated apoptosis. Further, no differential effect was observed in GYN cancer cells harboring wild type (A2780, OVCAR3, HELA, SIHA) or mutant (CP20, KLE, HEC1B) TP53. These data support further investigation of pharmacologic inhibitors of ATR in combination with existing platinum based therapeutics for treating GYN cancer. Citation Format: Pang-Ning Teng, Nicholas W. Bateman, Chad A. Hamilton, G. Larry Maxwell, Christopher J. Bakkenist, Thomas P. Conrads. Inhibition of ATR, but not ATM, sensitizes gynecologic cancer cells to cisplatin. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3758. doi:10.1158/1538-7445.AM2014-3758
Editorial comment: Endothelin: key to coronary vasospasm?
Authors: T Toyo-oka, T Sugimoto
Journal: Circulation (1991)

Advantages of 9Tc-Based AgentsUnder the heading "Physical Advantages of Tc-99m-Based Agents", Botvinick states without reference in his recent editorial, "The higher energy of emission will permit a larger administered dose with resultant high photon flux, allowing more refined collimation and providing high image quality with increased spatial resolution and reduced attenuation."'This is an overly ambitious claim and might mislead some readers.The higher emission energy has a minimal impact on radiation dosimetry and does not permit an increased administered dose per se.For a given radiation absorbed dose an increased administered dose of 'Tc agent is permitted by its shorter half-life, 6 hours, compared with 20`T1, 73 hours.More refined collimation is not permitted by the increased energy -quite the contrary.Increased spatial resolution is also not permitted by the higher energy in this application, because in imaging the moving heart cardiac motion is fundamentally limiting in spatial resolution.2The physical advantages of `SmTc myocardial perfusion agents accrue from the higher administered dose permitted, resulting in better statistical determination of images, producing increased contrast resolution, and the higher energy of 99"Tc can be expected to lead to fewer attenuation artefacts than 201T1.2
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
Authors: David C. Bäckström, Magdalena Eriksson Domellöf, Jan Linder, Bob Olsson, Annika Öhrfelt, Miles Trupp, Henrik Zetterberg, Kaj Blennow, Lars Forsgren
Journal: JAMA Neurology (2015)

Alterations in cerebrospinal fluid (CSF) have been found in Parkinson disease (PD) and in PD dementia (PDD), but the prognostic importance of such changes is not well known. In vivo biomarkers for disease processes in PD are important for future development of disease-modifying therapies.To assess the diagnostic and prognostic value of a panel of CSF biomarkers in patients with early PD and related disorders.Regional population-based, prospective cohort study of idiopathic parkinsonism that included patients diagnosed between January 1, 2004, and April 30, 2009, by a movement disorder team at a university hospital that represented the only neurology clinic in the region. Participants were 128 nondemented patients with new-onset parkinsonism (104 with PD, 11 with multiple system atrophy, and 13 with progressive supranuclear palsy) who were followed up for 5 to 9 years. At baseline, CSF from 30 healthy control participants was obtained for comparison.Cerebrospinal fluid concentrations of neurofilament light chain protein, Aβ1-42, total tau, phosphorylated tau, α-synuclein, and heart fatty acid-binding protein were quantified by 2 blinded measurements (at baseline and after 1 year). Follow-up included an extensive neuropsychological assessment. As PD outcome variables, mild cognitive impairment and incident PDD were diagnosed based on published criteria.Among the 128 study participants, the 104 patients with early PD had a different CSF pattern compared with the 13 patients with progressive supranuclear palsy (baseline area under the receiver operating characteristic curve, 0.87; P < .0001) and the 30 control participants (baseline area under the receiver operating characteristic curve, 0.69; P = .0021). A CSF biomarker pattern associated with the development of PDD was observed. In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein at baseline were related to future PDD as analyzed by Cox proportional hazards regression models. Combined, these early biomarkers predicted PDD with high accuracy (hazard ratio, 11.8; 95% CI, 3.3-42.1; P = .0001) after adjusting for possible confounders.The analyzed CSF biomarkers have potential usefulness as a diagnostic tool in patients with parkinsonism. In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein were related to future PDD, providing new insights into the etiology of PDD.
Mohs surgery for squamous cell carcinoma of the nail: report of 15 cases. Our experience and a long‐term follow‐up
Authors: E. Dika, B.M. Piraccini, R. Balestri, S. Vaccari, C. Misciali, A. Patrizi, P.A. Fanti
Journal: British Journal of Dermatology (2012)

Subungual squamous cell carcinoma (SSCC) is the most common malignancy of the nail unit. Mohs micrographic surgery (MMS) is a microscopically controlled surgical technique that has a high cure rate for skin cancers despite allowing narrow surgical margins.To evaluate the long-term effectiveness of MMS in the treatment of SSCC, and in particular its ability to reduce the number of digital amputations.Fifteen patients diagnosed with SSCC were treated with MMS as the first-line surgical approach, and were followed up for between 2 and 5 years.SSCC was completely excised in 13 patients, while two patients required amputation of the distal phalanx. For tumours with predominantly exophytic growth, clinical and radiological findings were found not to be reliable indicators of bone invasion. No recurrences were detected on follow-up.Our results show that MMS provides a high cure rate for SSCC and reduces the number of amputations needed. MMS should become the first-line surgical approach for SSCC.